期刊
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
卷 13, 期 5, 页码 379-400出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/15622975.2012.690535
关键词
Biomarker; attentention-deficit/hyperactivity disorder; olfaction; transcranial echosonography; neuroimaging; proteomics
类别
资金
- Deutsche Forschungsgemeinschaft [DFG KFO 125]
- AstraZeneca
- Bristol-Myers Squibb
- Janssen
- Lilly
- Lundbeck
- MEDICE
- Merz
- Novartis
- Pfizer
- Servier
- Shire
Objective. Psychiatric nosology is largely based on clinical phenomenology using convention-based diagnostic systems not necessarily reflecting neurobiological pathomechanisms. While progress has been made regarding its molecular biology and neuropathology, the phenotypic characterization of ADHD has not improved. Thus, validated biomarkers, more directly linked to the underlying pathology, could constitute an objective measure for the condition. Method. The task force on biological markers of the World Federation of Societies of Biological Psychiatry (WFSBP) and the World Federation of ADHD commissioned this paper to develop a consensus report on potential biomarkers of ADHD. The criteria for biomarker-candidate evaluation were: (1) sensitivity >80%, (2) specificity >80%, (3) the candidate is reliable, reproducible, inexpensive, non-invasive, easy to use, and (4) confirmed by at least two independent studies in peer-reviewed journals conducted by qualified investigators. Results. No reliable ADHD biomarker has been described to date, but some promising candidates (e. g., olfactory sensitivity, substantial echogenicity) exist. A problem in the development of ADHD markers is sample heterogeneity due to aetiological and phenotypic complexity and age-dependent co-morbidities. Conclusions. Most likely, no single ADHD biomarker can be identified. However, the use of a combination of markers may help to reduce heterogeneity and to identify homogeneous subtypes of ADHD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据